hydroxyproline has been researched along with Lung Diseases, Interstitial in 7 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with PC-SOD at 10 mg/kg significantly reduced the hydroxyproline content and fibrosis score." | 3.69 | Effect of lecithinized-superoxide dismutase on the interstitial pneumonia model induced by bleomycin in mice. ( Hori, Y; Horie, K; Hoshino, J; Miyauchi, S; Mizuno, S; Sekiguchi, T; Yamazaki, C, 1997) |
| "IL-18-/- mice showed much worse lung injuries than wild-type mice, as assessed by the survival rate, histological images, and leukocyte infiltration in the bronchoalveolar lavage fluid and myeloperoxidase activity." | 1.33 | Protection against bleomycin-induced lung injury by IL-18 in mice. ( Adachi, S; Fujita, Y; Kashiwamura, S; Kubota, A; Nakatani-Okuda, A; Okamura, H; Sekiyama, A; Tanizawa, T; Tsuji, Y; Ueda, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Y | 1 |
| Rong, M | 1 |
| Zhu, P | 1 |
| Chen, L | 1 |
| Fan, C | 1 |
| Wang, Y | 1 |
| Li, J | 1 |
| Fu, X | 1 |
| Zhao, L | 1 |
| Xiao, K | 1 |
| Wang, H | 1 |
| Wang, Z | 1 |
| Sun, L | 1 |
| Zhang, F | 1 |
| Zhang, X | 1 |
| Tang, F | 1 |
| He, W | 1 |
| Matsui, K | 1 |
| Ueda, H | 2 |
| Terada, M | 1 |
| Azuma, N | 1 |
| Okamura, H | 2 |
| Sano, H | 1 |
| Li, Y | 1 |
| Azuma, A | 1 |
| Takahashi, S | 1 |
| Usuki, J | 1 |
| Matsuda, K | 1 |
| Aoyama, A | 1 |
| Kudoh, S | 1 |
| Nakatani-Okuda, A | 1 |
| Kashiwamura, S | 1 |
| Sekiyama, A | 1 |
| Kubota, A | 1 |
| Fujita, Y | 1 |
| Adachi, S | 1 |
| Tsuji, Y | 1 |
| Tanizawa, T | 1 |
| Yamazaki, C | 2 |
| Hoshino, J | 2 |
| Hori, Y | 2 |
| Sekiguchi, T | 2 |
| Miyauchi, S | 2 |
| Mizuno, S | 2 |
| Horie, K | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for hydroxyproline and Lung Diseases, Interstitial
| Article | Year |
|---|---|
[The circulating fibrocytes are associated with the lung inflammation and fibrosis of mice with interstitial lung disease].
Topics: Actins; Animals; Arthritis, Experimental; Bleomycin; Collagen Type I; Female; Flow Cytometry; Hydrox | 2014 |
Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.
Topics: Actins; Animals; Bleomycin; Blotting, Western; Cell Differentiation; Cells, Cultured; Collagen Type | 2009 |
Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.
Topics: Actins; Animals; Bleomycin; Blotting, Western; Cell Differentiation; Cells, Cultured; Collagen Type | 2009 |
Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.
Topics: Actins; Animals; Bleomycin; Blotting, Western; Cell Differentiation; Cells, Cultured; Collagen Type | 2009 |
Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.
Topics: Actins; Animals; Bleomycin; Blotting, Western; Cell Differentiation; Cells, Cultured; Collagen Type | 2009 |
Mizoribine protects against bleomycin-induced lung injury.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Bronchoalveolar Lavage Fluid; Cell Count; Cell Prol | 2010 |
Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice.
Topics: Animals; Anti-Bacterial Agents; Bleomycin; Bronchoalveolar Lavage Fluid; Cell Movement; Disease Mode | 2002 |
Protection against bleomycin-induced lung injury by IL-18 in mice.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Bronchoalveolar Lavage Fluid; Female; Granulocyte-M | 2005 |
Effect of lecithinized-superoxide dismutase on the interstitial pneumonia model induced by bleomycin in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Disease Models, Animal; Fibrosis; Hydroxyprolin | 1997 |
Production of superoxide and nitric oxide by alveolar macrophages in the bleomycin-induced interstitial pneumonia mice model.
Topics: Animals; Anti-Bacterial Agents; Bleomycin; Disease Models, Animal; Hydroxyproline; Immunohistochemis | 1998 |